R&D News | pharmaphorum

News

UK launches total-body PET drive to support drug discovery

The UK has launched an initiative that will coordinate the activities of two total-body PET imaging centres in England and Scotland, harvesting data that will be made avai

News

Boehringer moves obesity therapy into phase 3

Boehringer Ingelheim and Zealand Pharma have kicked off three phase 3 trials of obesity drug candidate survodutide, in patients with and without diabetes, in the hope of b

News

uniQure sheds a fifth of its staff and half its R&D

Netherlands gene therapy company uniQure has said it will shed 20% of its workforce, around 114 jobs, and slash its R&D projects in an effort to extend its cash reserv

News

Sanofi buys into Teva’s anti-TL1A therapy for IBD

In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva

News

UK Biobank study “will shape drug discovery”

A landmark study drawing on data from UK Biobank has generated a first-of-its-kind dataset of the interactions between genes and proteins that could unlock myriad avenues for research

News

Moderna eyes 2025 approval for COVID, flu combination jab

Moderna’s combined mRNA-based vaccine for COVID-19 and seasonal influenza has been shown to be at least as effective as jabs given separately in a phase 1/2 trial, setting

UK launches total-body PET drive to support drug discovery

Boehringer moves obesity therapy into phase 3

uniQure sheds a fifth of its staff and half its R&D

Sanofi buys into Teva’s anti-TL1A therapy for IBD

UK Biobank study “will shape drug discovery”

Moderna eyes 2025 approval for COVID, flu combination jab

Treating the chronic diseases GLP-1s miss, with Laurent Auda...

How to meet your physicians where they are online

News

Editor's Picks